Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML0277

Sigma-Aldrich

Methylnaltrexone bromide

≥97% (HPLC)

Synonym(s):

17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium bromide, MNTX, Methylnaltrexonium, Mrz-2663, N-Methylnaltrexone, Naltrexone MB, Quaternary ammonium naltrexone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H26NO4 · Br
CAS Number:
73232-52-7
Molecular Weight:
436.34
MDL number:
MFCD06407831
UNSPSC Code:
12352200
PubChem Substance ID:
329825285
NACRES:
NA.77

Quality Level

100

Assay

≥97% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: ≥5 mg/mL

shipped in

wet ice

storage temp.

−20°C

SMILES string

[Br-].C[N@+]1(CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@]2(O)CCC4=O)c35)CC6CC6

InChI

1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22?;/m1./s1

InChI key

IFGIYSGOEZJNBE-KNLJMPJLSA-N

Gene Information

human ... OPRM1(4988)

Looking for similar products? Visit Product Comparison Guide

General description

Methylnaltrexone does not cross blood brain barrier and does not affect the opioid effects in the brain, such as analgesia. It is used to treat opioid-induced constipation (OIC).

Application

Methylnaltrexone bromide has been used as a drug to measure plasma protein binding (PPB), permeability (Pm) and the membrane coefficient (KIAM) for the prediction of blood brain barrier (BBB) penetration. It is also used as a mu-opioid receptor (MOR) antagonist to abrogate morphine tolerance and opioid-induced hyperalgesia (OIH).

Biochem/physiol Actions

Methylnaltrexone bromide is a narcotic antagonist. It is a peripheral mu-opiod receptor antagonist that cannot cross the blood-brain barrier. It reverses many opioid side-effects without interfering with pain relief.

Features and Benefits

This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H371

Hazard Classifications

STOT SE 2 Oral

Target Organs

Gastrointestinal tract

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Florian Pfab et al.
Current opinion in clinical nutrition and metabolic care, 15(2), 166-173 (2012-01-12)
Gastrointestinal motility disorders (GMDs) are common in the ICU. When encountering these problems, one typically thinks of prokinetics. This review summarizes current evidence of treatments. Prokinetics are not the first-line therapy for GMDs. In fact, the clinical implications of using
Sergio B Sawh et al.
Mayo Clinic proceedings, 87(3), 255-259 (2012-03-06)
Gastrointestinal dysmotility and constipation are common problems in critical care patients. The majority of critical care patients are treated with opioids, which inhibit gastrointestinal (GI) motility and lead to adverse outcomes. We reasoned that methylnaltrexone (MNTX), a peripheral opioid antagonist
L Garten et al.
Archives of disease in childhood. Fetal and neonatal edition, 97(2), F151-F153 (2011-10-29)
Methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, has been studied in adults for the treatment of opioid-induced constipation in advanced illness. Here, the authors document the first neonate to receive methylnaltrexone in an attempt to resolve morphine-induced urinary retention. An
Edward Michna et al.
Pain medicine (Malden, Mass.), 12(8), 1223-1230 (2011-08-04)
Methylnaltrexone, a selective peripherally acting mu-opioid receptor antagonist, effectively treats opioid-induced constipation (OIC) in patients with advanced illness and shows efficacy in patients with chronic nonmalignant pain. The objective was to identify patients who achieved maximal treatment effect based on
Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients.
Slatkin N, et al.
The Journal of Supportive Oncology, 7(1), 39-46 (2009)
View All Related Papers

Articles

Opioid Receptors

We offers many products related to opioid receptors for your research needs.

Opioid Receptors

We offers many products related to opioid receptors for your research needs.

Opioid Receptors

We offers many products related to opioid receptors for your research needs.

Opioid Receptors

We offers many products related to opioid receptors for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service